Margin collapse masks a quarter that missed on every absolute
Revenue down 7.8% and PAT down 33.7% against guidance of +20–25% growth and 18–19% margins. The pipeline remains strong, but execution risk has moved centre-stage and the market is pricing it in.
Arkade Developers reported Q1 FY-2027 revenue of ₹147 Crore, down 7.8% year-on-year. Net profit fell to ₹19.1 Crore, a 33.7% decline. Both figures sit far below management's prior guidance of 20–25% revenue growth and 18–19% PAT margins. The EBITDA margin compressed to 18.9% from the historical range of 26–27%, and management has now cut full-year EBITDA guidance to 25–26%. That miss on every absolute, paired with margin contraction that management attributes partly to a 30% headcount expansion and lower investment income, is the operational story. The pipeline narrative—₹12,800 Crore in development visibility and a doubling of FY27 launch ambition to ₹3,000 Crore—remains bullish. But the market has priced in near-term execution risk: the stock fell 3.21% on day 1 and has not recovered.
Revenue and profit: where the miss sits
₹147 Cr
YoY -7.8% vs guidance +20–25%
₹19.1 Cr
YoY -33.7% vs guidance +18–19% margin
18.9%
vs 26–27% prior; guidance now 25–26%
29.1%
stable YoY; pricing power intact
The gross margin—29.1%—held steady, signalling that Arkade has not lost pricing power despite the slowdown in the overall Mumbai residential market. But the EBITDA decline of 750 basis points year-on-year reveals the operating-leverage problem: fixed costs are not absorbing into revenue fast enough. Two drivers: employee headcount grew from 213 to 277 (a 30% expansion to support pipeline development), and other income fell as IPO-linked returns declined relative to prior year. Neither is a one-time item. The headcount build is structural—management is investing to execute the ₹12,800 Crore pipeline. The investment-income reset is real and will persist as a baseline. Together, they created a margin hole that management is now managing downward: guidance was 27–28% EBITDA; delivered is 25–26%.
What management claimed vs. what holds up
"Steady operational performance with healthy customer demand"
→ Revenue down 7.8% YoY; PAT down 33.7% YoY. Contradicted.
"Gross margins remain resilient at 29.1%"
→ Confirmed; but EBITDA at 18.9% vs 26–27% prior shows operating-leverage failure. Supported in isolation; misleading in context.
"EBITDA margins normalise to 25–26% going forward"
→ Prior guidance was 27–28%. This is a cut, not a normalisation. Overstated.
"Pipeline of ₹12,800 Crore provides visibility for growth"
→ Pipeline is real; but FY27 pre-sales guidance of ₹1,000 Crore implies ~8% growth (₹1,000 Cr vs ₹155 Cr Q1 × 4 ≈ ₹620 Cr annualised run-rate). That is soft, not accelerated. Partially overstated.
"Pre-sales up 9% YoY reflecting customer confidence"
→ The growth is real; but 9% is well below the 20–25% guidance implied by prior revenue targets. Partial; momentum is soft.
What changed on this call
The strategic posture has shifted on one axis but held on another. Margin guidance was cut (not volunteered, but confirmed under analyst pressure). The full-year pre-sales target of ₹1,000 Crore implies cautious near-term momentum. But the FY27 launch ambition has doubled to ₹3,000 Crore—a signal that management is still convict on the redevelopment tailwind and the Malad/Thane execution. This is management betting the farm on H2 FY27 launch success to drive H2/H3 pre-sales velocity. The balance sheet has not changed; net debt remains at ₹5 Crore, providing war-chest flexibility for construction finance if needed.
The bull case and the bear case
Development pipeline of ₹12,800 Cr provides 5–6 year visibility; redevelopment is a structural tailwind in Mumbai due to land scarcity.
Gross margin of 29.1% proves pricing power; Arkade is not discounting or losing negotiating leverage.
Net debt of ₹5 Crore (0.01× equity) is fortress-like; no refinancing risk, no equity dilution needed.
FY27 launch ambition of ₹3,000 Cr shows management conviction; if executed, could drive material pre-sales acceleration in H2/H3.
Pre-sales up 9% YoY despite geopolitical macro headwinds; customer confidence not fully eroded.
Revenue -7.8% YoY vs +20–25% guidance: miss of ~28 percentage points on the headline metric.
PAT -33.7% YoY vs +18–19% margin guidance: miss of ~31 percentage points on the profit metric.
EBITDA margin at 18.9% vs 26–27% historical: 750 bps compression is not temporary if employee costs are structural.
EBITDA guidance cut to 25–26% mid-year; no timeline or plan communicated for how to absorb employee-cost headwind.
Pre-sales growth of 9% YoY is well below the 20–25% revenue guidance trajectory; near-term momentum is soft.
₹3,000 Cr FY27 launch plan is 2× historical maximum; execution risk is unproven at this scale.
Management framed Q1 as "steady" despite material absolute misses on revenue and profit; credibility erosion.
Ranked risks: what should concern a holder
1
High
Malad (₹750 Cr GDV, Q3) and Thane (₹2,000 Cr, Q4) together are unprecedented for Arkade. Approval delays, construction ramp-up bottlenecks, or weak market reception would crater FY27 pre-sales and force guidance cuts. Management's 'precedent is limited' exposure here.
Launch execution at 2× historical scale
2
High
Employee costs spiked 30% (213→277 headcount) and are now built into the cost base. If revenue growth doesn't accelerate, the 25–26% EBITDA guidance becomes unrealistic. Further downside to 22–24% would signal operating-leverage failure and likely trigger another cut.
EBITDA margin recovery stalled
3
Medium
9% YoY growth is half the historical trajectory. If Malad/Thane launches convert at <20% attachment (management's own historical assumption), the FY27 ₹1,000 Cr pre-sales target will be missed, and momentum enters Q3 broken.
Pre-sales momentum remains soft
4
Medium
Anand Nagar (top-3 portfolio by GDV) is dependent on wireless station relocation (FY27) and approvals (FY28) before FY29 launch. Filmistan approval timeline unconfirmed. Regulatory risk on height restrictions and zoning in MMR redevelopment clusters is real.
Approval and regulatory delays
5
Low
Large-scale launches may require incremental construction finance. If rates spike or refinancing becomes costly, project unit economics could compress. However, net debt is minimal (₹5 Cr), so headroom exists for now.
Construction finance and interest-rate risk
How the street is positioned
The market reaction tells the story: day 1 sell-off of 3.21% after the result announcement, and the decline lingered at −0.46% by day 3. The initial pop did not hold; institutional investors treated the print as a miss worth exiting. That verdict is now embedded in the stock's technicals. At ₹130.44, Arkade is trading 25.88% below its all-time high of ₹175.99—a significant mark-down from peak optimism. Against the 52-week range, the stock is +40.83% off the low of ₹92.62, so recovery has occurred from the worst. But it sits below the 20-day moving average (₹136.95), a short-term negative signal, though above the 50-day (₹129.21) and 200-day (₹128.93) averages—mixed technicals.
The most damning institutional signal: foreign institutional ownership has collapsed. FII holdings plummeted from 1.22% in FY25 Q1 to just 0.13% in Q1 FY27—a 109 basis point exodus. That is a 90% reduction in foreign capital exposure. By contrast, domestic institutions hold only 0.08%, and promoters hold 71.19%. The FII retreat signals a loss of confidence in near-term execution or margin recovery. Foreign investors have decided to re-allocate capital elsewhere in the Indian real-estate space, likely toward better-performing developers with higher near-term visibility.
1 · Q2 FY27 pre-sales and EBITDA margin (due Oct-Nov 2026)
Pre-sales should show sequential acceleration if Malad/Thane launch momentum is building. EBITDA margin should move toward 22–24% if employee-cost absorption is on track. If both remain soft, the full-year guidance will be at risk and the stock will likely test new lows.
2 · Malad redevelopment launch execution (Q3 FY27, Oct-Dec 2026)
The 750-crore GDV project is the first real test of management's ability to execute at scale. Market reception, pre-sales conversion, and construction ramp-up will signal whether the ₹3,000 Cr FY27 plan is credible or aggressive.
3 · Management margin recovery narrative
Executives need to articulate how employee costs (now +30% YoY) will be absorbed into EBITDA as revenue scales. Without a credible bridge from 18.9% (Q1 actual) to 25–26% (full-year guidance), the stock will remain under pressure and FII may not return.
The number to track
EBITDA margin trajectory. If Q2 EBITDA margin moves toward 22–24% (up from 18.9% in Q1), the recovery narrative gains traction. If it stays pinned near 18–19%, management's 25–26% full-year guidance becomes unrealistic and will trigger another cut. The margin number is the single indicator of whether the quarter was a one-quarter dip or the start of a structural erosion.
Arkade Developers had a soft quarter masked by a strong pipeline narrative. The company is betting the next six months on execution—doubling its launch ambition to ₹3,000 Crore and banking on pre-sales acceleration in H2 FY27. The market is not convinced: FII has retreated, the stock is down from ATH, and guidance was cut, not raised.
This is not a buy on the pipeline; it is a hold on the execution plan. Wait for proof in the form of Malad launch success and visible pre-sales traction in Q2, or wait for management to credibly address the margin collapse. Until then, the risk-reward is balanced at best, and skewed toward near-term disappointment.
FY27 Inflection Point: Presales from Filmistan & Thane Set to Flow
After anchoring FY26 with 17% presales growth and modest revenue uptick, Arkade enters Q1 FY27 as a transition quarter. The board meets Aug 11 to approve unaudited results; the Street will be watching whether Filmistan (₹3,000 Cr GDV luxury towers) and Thane (₹2,000 Cr GDV mixed-use) have begun converting into presales. Management guides for presales pickup in FY27, but cautious analysts flag margin compression — the company's operating profit has grown just 3.7% CAGR over five years while revenue grew 13.4%. A preview.
The Setup
Arkade enters Q1 FY27 at a pivotal juncture. FY26 delivered 19% revenue growth to ₹828 Cr and 17% presales growth to ₹901 Cr — solid, but margins remain under pressure. Management has guided for FY27 as an inflection year, anchored on two marquee launches: Filmistan (₹3,000 Cr GDV ultra-luxury 4-acre towers in Goregaon West, 2 x 50-storey buildings) and Thane (₹2,000 Cr GDV mixed-use, valued at ₹172.48 Cr including stamp duty). The real question for Q1: have these projects begun to move? The board meets tomorrow (Aug 11) to approve unaudited results; Street will scrutinize presales trajectory and whether management's FY27 guidance holds.
~₹200–250 Cr
Management guides FY27 as inflection year; Q1 likely reflects early Filmistan & Thane momentum. FY26 quarterly presales averaged ~₹225 Cr.
~₹190–220 Cr
Transition quarter — FY26 Q4 contributed ₹243 Cr. Q1 FY27 reflects cash realization from prior launches (Santacruz Sapphire, ongoing projects) plus early Filmistan/Thane presales-to-cash conversion.
~22–26%
FY26 showed margin headwinds (operating profit growth 3.7% CAGR vs revenue 13.4% CAGR). Street is watching whether Filmistan luxury positioning lifts margins or if scale challenges persist.
₹140–210 range
Stock at ₹134.54 as of Aug 10 — trades below consensus. Limited institutional coverage; MarketsMOJO rates Sell, citing modest long-term growth and technical headwinds.
What Strong vs Weak Looks Like
Strong Q1: Presales ≥₹240 Cr with visible Filmistan/Thane traction (both launches confirmed at investor meetings or disclosures); revenue ≥₹215 Cr; EBITDA margin ≥25% (suggesting operational leverage kicking in). Evidence that luxury positioning is resonating and that large-project execution is on track. Guidance for full-year presales >₹1,000 Cr would be a major signal. Weak Q1: Presales <₹180 Cr (suggesting Filmistan/Thane slower to convert, or competitive headwinds in residential); revenue <₹185 Cr (cash realization miss); EBITDA margin <22% (margin compression deepens). Any commentary on project delays, cost overruns, or missed launches would trigger concern. Cautious FY27 guidance or presales guide cut would be read as inflection delayed.
On Track?
Management has positioned FY27 as a turning point — presales and revenue growth set to reaccelerate as Filmistan (luxury anchor) and Thane (volume play) ramp. Prior trajectory supports this: FY25–FY26 presales growth was 17%, and management's capex on these acquisitions (₹183 Cr for Filmistan, ₹172.48 Cr for Thane land) signals serious commitment. However, the real proof is in Q1 presales. If Filmistan/Thane presales run >₹60 Cr combined in Q1, Street will gain confidence in the FY27 thesis. If they are negligible or delayed, the narrative inverts: Arkade remains a modest-growth residential developer with margin headwinds, not an inflection story.
What the Street Says
Since Last Quarter
Arkade filed several material updates in the 6 weeks since FY26 close (May 27, 2026). On May 29, it announced acquisition of ₹1,100 Cr Kandivali East redevelopment rights (9 societies cluster, ~1.02 Ac). This adds to the Filmistan/Thane pipeline and diversifies Arkade's future revenue mix. On Jul 10, Arkade received a ₹13.74 L GST demand order (Thane Commissionerate) — a procedural tax matter, flagged for disclosure but routine for the sector. More concerning: on Jul 28, the company disclosed an FIR against its former Chief Sales Officer (Mrs. Amita Singh) for alleged ₹2 Cr fraud/customer fund diversion. Arkade said the matter is with authorities; no quantified P&L impact disclosed yet. On Jul 30, Arkade launched Arkade Sapphire in Santacruz West (boutique residential + commercial) — positive new-supply signal. Ownership is stable: promoter 71.19% (unchanged), FII 0.13%, DII 0.08% (minimal institutional interest).
1 · Filmistan & Thane Presales
Are either project showing >₹30–40 Cr presales in Q1? Any project launch updates or customer pipeline commentary? If both remain silent or low, the inflection thesis is at risk.
2 · Margin Trajectory
Does EBITDA margin hold ≥24% in Q1, or does it slip further? Any quantified impact from GST penalty or CSO fraud on costs/receivables? Margin recovery is the Street's #1 skepticism — watch closely.
3 · FY27 Guidance & Presales Outlook
Management's full-year FY27 presales guidance is crucial. A target >₹1,000 Cr (vs ₹901 Cr in FY26) confirms Filmistan/Thane ramp. A guidance miss or cut would signal execution risk or competitive headwinds. Also: any commentary on Kandivali redevelopment timelines or land acquisition costs?
Arkade's Q1 FY27 result is a litmus test for management's inflection thesis. The company has assembled a credible pipeline — ₹5,000 Cr GDV in Filmistan & Thane, plus Kandivali redevelopment — but the proof is presales traction and margin recovery. Street is skeptical (thin coverage, Sell-rated, technical headwinds), and the stock trades below consensus target. If Q1 shows Filmistan/Thane momentum and EBITDA margin stabilization, narrative resets toward 2026–2027 re-rating. If presales remain modest and margins compress further, Arkade remains a modest-growth story with execution risk. Board approves results on Aug 11; report date TBD but likely within days.
Pipeline growth delayed; margins compressed mid-execution
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Missed revenue (−7.8% vs +20-25%) and PAT (−33.7% vs +18-19% target) guidance; EBITDA margin lowered 200 bps mid-year.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered a soft quarter with -7.8% revenue and -33.7% PAT declines, and EBITDA guidance was cut from 27-28% to 25-26%. However, the ₹12,800 Cr development pipeline and redevelopment tailwind offer multi-year upside if execution delivers. Key risk: margin pressure persists and ₹3,000 Cr launch execution is untested at this scale.
₹147 Cr
Revenue · −7.8% YoY₹19.1 Cr
Reported PAT · −33.7% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Steady operational performance with healthy customer demand
MISSRevenue down 7.8% YoY; PAT down 33.7% YoY
Gross margins remain resilient at 29.1%
METGross margins at 29.1%, confirmed; but EBITDA margin at 18.9% vs historical 26-27%
EBITDA margins normalise to 25-26% going forward
OVERSTATEDPrior guidance was 27-28%; current guidance of 25-26% is a reduction
Pipeline of ₹12,800 Cr provides visibility for growth
OVERSTATEDPipeline confirmed at ₹12,800 Cr across 4.2M sqft; but FY27 pre-sales guidance of ₹1,000 Cr implies only 8% implied growth
Pre-sales up 9% YoY to ₹155 Cr reflecting customer confidence
PartialPre-sales up 9% YoY; but guidance was 20-25% revenue growth, so 9% pre-sales growth is soft
Earnings quality
What changed since the last call
EBITDA margin guidance cut
DowngradePrior 27-28% target → now targeting 25-26% for FY27. Management attributes to employee cost expansion (213→277 headcount, +30%) and lower investment income. Acknowledged cost inflation absorption challenge.
FY27 revenue growth decelerated
DowngradeQ1 actual revenue ₹147 Cr down 7.8% YoY vs prior 20-25% growth guidance. Pre-sales up only 9% YoY, signalling soft near-term momentum.
Launch pipeline accelerated
UpgradeDevelopment pipeline now ₹12,800 Cr (up from ₹12,000 Cr prior). FY27 launch plan ₹3,000 Cr (2x historical ₹1,500 Cr), with ₹5,000+ Cr planned for FY28.
Leverage remains minimal
NeutralNet debt only ₹5 Cr, net debt-to-equity 0.01x. Unchanged; provides flexibility for construction finance, not equity raises.
The Q&A
Analysts pressed hard on margin compression (Dhananjay: 26-27% → <20%, why?). Samshet held firm at 25-26% target, blaming employee costs and investment income. Kedar questioned Anand Nagar delay (FY29 vs earlier expectations); Amit explained wireless station relocation blocking approvals until FY27-FY28. Gaurav queried why ₹3,000 Cr launches yield only ₹500 Cr FY27 pre-sales; Amit justified conservatism (launches Q3-Q4 don't yield full-year sales). Management composed but defensive on execution risks.
Margin guidance, FY27 pre-sales — Dhananjay Mishra, Centrum Broking
PartialGross margin stable at 29%. EBITDA decline due to lower other income and higher employee costs. We expect to maintain EBITDA margin of 25-26% over the year.
Anand Nagar project timeline — Kedar, NAN Partners
AnsweredNo delays. Wireless station in Dahisar currently restricts building approvals due to height limits. Station shifting to Madh Marve expected FY27, approvals FY28, launch FY29. MOU already signed with society.
Accelerated growth quantification — Sahil Patani, Strokes Capital
AnsweredShift from ₹1,500 Cr to ₹3,000 Cr launches is 100% growth. Next year ₹5,000+ Cr launches planned. These are spikes in growth.
Launch pipeline readiness, delays — Rohit, Individual Investor
AnsweredProjects at various stages. BD starts, then approval, then launch, then construction. Q3: Malad redevelopment ₹750 Cr. Q4: Thane ₹2,000 Cr. Santa Cruz already launched. Combined ₹3,000 Cr potential.
Construction cost inflation, funding needs — Rahul Shah, Eternal Capital
AnsweredConstruction cost inflation absorbed by incremental unit prices, balances out. Outright projects already paid for. Near net-debt currently. May opt for construction finance at lower rates if needed.
Land acquisition cost discipline — Soham Joshi, Individual Investor
PartialVery disciplined in acquisition. Don't do fancy acquisitions, focus on value transactions with healthy margins. Each manager has clear role (redevelopment, outright, JDAs).
FY27 pre-sales outlook vs launches — Gaurav Patil, Individual Investor
Answered₹3,000 Cr completes over 4 years = ₹750 Cr/year avg. Historically ~20% sales upon launch = ₹600 Cr, conservatively ₹500 Cr. Q3-Q4 launches don't yield full-year benefit.
Demand sustainability, redevelopment outlook — Pranav, Individual Investor
AnsweredPresent only in mature, established markets (e.g. not SRA/weaker segments). Aspiring segment focus. Redevelopment will be higher due to land scarcity in MMR and abundance of older buildings.
Guidance
FY27 pre-sales ₹1,000 Cr (₹500 Cr new launches, ₹500 Cr ongoing)
Medium₹3,000 Cr launches planned Q3-Q4 expected to yield ~₹750 Cr/year on 4-year completion cycle. Q3-Q4 partial-year sales conservatively pegged at ₹500 Cr. Dependent on successful launch execution.
FY28 ₹5,000+ Cr launches planned
MediumIncludes Filmistan and 2 additional major projects. Full-year benefit should drive higher pre-sales, but Filmistan approval/execution timeline not confirmed. Macro dependent.
EBITDA margin target 25-26% for FY27 (down from 27-28% prior)
LowCurrent Q1 EBITDA margin 18.9% due to employee cost spike (213→277 headcount, +30%) and lower investment income. Management attributes to temporary factors but provides no timeline for normalization. Risk of further compression if employee costs remain sticky.
PAT margin 18-19% (as per prior target, now unquantified)
LowQ1 PAT margin 13% vs 18-19% target. Management did not re-confirm PAT margin guidance this call. Margin recovery dependent on scaling revenues and absorbing employee cost headwind.
Outright projects already paid for; may use construction finance for launches
HighLand acquisitions funded. Construction finance preferred over equity to avoid dilution. Net-debt minimal at ₹5 Cr, flexibility intact.
Risks the call surfaced
Launch execution
High₹3,000 Cr FY27 launches (Malad ₹750 Cr, Thane ₹2,000 Cr) are 2x historical scale. Coordination, approvals, and construction ramp-up untested. Delays would compress FY27 pre-sales materially.
Margin compression
HighEBITDA margin at 18.9% vs 26-27% historical; guidance cut to 25-26%. Employee costs spiked 30% (213→277 headcount). Fixed-cost absorption lag could persist if revenue growth remains soft.
Pre-sales momentum
MediumPre-sales up only 9% YoY (₹155 Cr) vs prior revenue guidance of 20-25% growth. Soft pre-sales momentum suggests FY27 pre-sales target of ₹1,000 Cr may be at risk if new launches underperform.
Approval/regulatory delays
MediumAnand Nagar (top-3 GDV project) delayed to FY29 due to wireless station relocation in Dahisar. Filmistan approval timeline not confirmed. Height-restriction regulatory changes in MMR could impact other projects.
Financing/refinancing
LowLarge-scale launches may require construction finance; interest-rate risk if borrowing costs rise. Currently at net debt ₹5 Cr but leverage could spike during peak construction period.
Management
Score 6/10. Amit Jain articulate on strategy and pipeline but vague on near-term margin recovery timeline. Samshet Shetye transparent on cost drivers (employee, investment income) but defensive when pressed on margin miss. No new forward-margin quantification provided; relies on '25-26%' assertion without path to recovery. Track record mixed: pre-sales up 9% YoY vs 20-25% revenue guidance—significant miss. Gross margins intact but operating expense control weak (employee costs +30% offsetting revenue). Pipeline expanded (₹12,000→₹12,800 Cr) despite soft quarter—positive signal on BD discipline.
1 · Q3 FY27 (Oct-Dec 2026)
Malad redevelopment launch, ₹750 Cr GDV planned
2 · Q4 FY27 (Jan-Mar 2027)
Thane project launch, ₹2,000 Cr sale potential; total Q3-Q4 ₹3,000 Cr launches
3 · FY28
Filmistan and 2 additional large projects planned; ₹5,000+ Cr launch pipeline
Key risk: margin pressure persists and ₹3,000 Cr launch execution is untested at this scale.
Arkade Q1 FY27: PAT down 34% YoY to ₹19.1 Cr, revenue -8%, margins compress vs guidance
PAT -33.65% YoY · revenue -7.83% · margins compressing
₹146.97 Cr
-7.83% YoY
₹19.08 Cr
-33.65% YoY
12.83%
-4.6pp YoY
₹1.03
Arkade Developers' consolidated Q1 FY27 (quarter ended June 30, 2026) revenue fell 7.8% YoY to ₹146.97 Cr from ₹159.45 Cr, and consolidated PAT fell 33.6% YoY to ₹19.08 Cr from ₹28.76 Cr, with basic EPS down to ₹1.03 from ₹1.55. Standalone tells the same story (revenue ₹146.97 Cr, PAT ₹19.21 Cr) — the two bases converge this quarter, no material divergence to flag.
Q1 FY-2027 vs prior quarters
Sequentially, PAT swung from a ₹109.57 Cr consolidated loss in Q4 FY26 to a ₹19.08 Cr profit, but that is not an operating turnaround: the Q4 loss was driven entirely by a ₹182.17 Cr one-off impairment on Arkade's investment in Filmistan Private Limited (tenancy-rights write-down under Ind AS 36, following an NCLT-approved demerger); this quarter carries no exceptional items. On an operating basis, margins actually compressed YoY — OPM (on revenue from operations) fell to ~18.9% from 21.5%, and NPM fell to 12.8% from 17.4% a year ago, as cost of construction and employee expenses grew faster than revenue.
The stock went into the print at ₹133.96, down 4.9% over the past month of trading.
Management projects a revenue growth of 20-25% year-on-year for the next 2-3 years, with potential for exponential growth in FY28-FY29 driven by the Filmistan and Thane projects. The company targets EBITDA margins of 27-28% and PAT margins of 18-19%. A significant project pipeline of approximately Rs. 12,000 crores is
— This quarter: missed
Against management's own guidance from the Q4 FY26 concall — 20-25% YoY revenue growth for the next 2-3 years, EBITDA margins of 27-28%, PAT margins of 18-19%, and a ~₹12,000 Cr project pipeline over 5-6 years — this quarter missed on every count: revenue declined instead of growing, and both margin lines trail target by 800-1,000+ bps. The confident, bullish tone from that prior call is not yet borne out in the numbers. We found no analyst/brokerage consensus estimates published for this specific quarter, so vsStreet is unknown rather than assumed; management also issued no press release alongside this filing to frame the print. On the corporate side, the company launched Arkade Sapphire in Santacruz West (July 30, 2026), a step toward the stated pipeline target, and appointed new senior management (June 18) shortly before the auditors' Emphasis of Matter flagged an FIR against a former senior employee (CSO) over alleged diversion of customer transactions, brokerage-related financial gain, and forged parking-space agreements involving ~₹2 Cr; no financial adjustment has been made to the results pending the investigation's outcome.
W1
Outcome and quantified financial impact of the FIR investigation into the former senior employee's alleged misconduct (auditors' Emphasis of Matter, unresolved as of this filing).
W2
Whether revenue reaccelerates toward management's guided 20-25% YoY growth — this quarter printed -7.8% YoY, a clear miss against that target.
W3
EBITDA/PAT margin trajectory toward the 27-28%/18-19% targets — current quarter at ~18.9% OPM / 12.8% NPM, both trailing guidance.